Business Context and Reporting Period
Company: OS Therapies Inc (OSTX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 9, 2025
Event: Completion of acquisition of Lm-based immune-oncology programs and related intellectual property assets (the "HER2 Assets") from Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.).
Key Financial Metrics and Transaction Details
Transaction Consideration: Aggregate purchase price of $8,000,000 paid as follows:
- Cash: $500,000 total ($400,000 to Ayala; $100,000 to a third party on behalf of Ayala).
- Equity: $7,500,000 worth of common stock (4,774,637 shares based on 30-day VWAP).
Equity Issuance Structure: Due to NYSE ownership limitations (19.99% cap), the issuance was structured as:
- 2,164,215 shares of common stock issued immediately ("Initial Shares").
- Warrant to purchase 2,166,381 shares ("Warrant Shares") at an exercise price of $0.001, expiring in three years.
- Remaining 444,041 shares ("Additional Consideration Shares") to be issued upon stockholder approval, or converted to a warrant if ownership would exceed 9.99%.
Assets Acquired: Two Investigational New Drug (IND) filings with the FDA:
- ADXS-503 for Non-Small Cell Lung Cancer.
- ADXS-504 for Prostate Cancer.
Material Changes and Financial Impact
The acquisition resulted in significant reductions to future contingent liabilities and royalty obligations:
- Eliminated Milestone Payments: $3,500,000 payment owed upon first FDA Biologics Licensing Authorization approval for OST-HER2.
- Eliminated Sales Milestones: Total of $16,500,000 in sales milestones previously owed to Ayala (triggers at $20M, $50M, and $100M cumulative sales).
- Reduced Royalty Rate: Royalty consideration on OST-HER2-related sales reduced from 10% of net sales (owed to Ayala) to 1.5% of net sales (owed to the Trustees of the University of Pennsylvania). This 1.5% rate applies to OST-HER2, ADXS-503, ADXS-504, and new candidates from the Lm platform.
Lock-Up Agreement: Ayala agreed not to trade or transfer Consideration Shares for 180 days following closing.
Guidance, Outlook, and Risks
Regulatory Requirements: The Company must file registration statements for the resale of shares within 75 days of closing. Issuance of the "Additional Consideration Shares" is contingent upon obtaining stockholder approval in accordance with NYSE American LLC Company Guide Section 713.
Risks and Contingencies:
- Dilution Risk: The transaction involves a significant issuance of equity (approx. 4.77M shares plus warrant coverage), subject to ownership caps.
- Regulatory Approval: Future value depends on FDA approval of the acquired INDs (ADXS-503 and ADXS-504).
- Market Conditions: The value of the equity consideration was based on a 30-day volume-weighted average price; future stock price volatility affects the effective cost of the acquisition.
Management Commentary: The filing does not provide specific forward-looking financial guidance or revenue projections beyond the transaction details.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess the dilution impact of the 4,774,637 Consideration Shares.
- Confirm the status of the stockholder approval required for the issuance of the remaining 444,041 shares.
- Review the full text of the Asset Purchase Agreement (Exhibit 10.1) for any undisclosed liabilities assumed.
- Monitor the 180-day lock-up expiration date for potential selling pressure from Ayala.
- Track the progress of the INDs (ADXS-503 and ADXS-504) through the FDA approval process.